IGC Pharma, Inc.: Form 10-Q for the period ended Sep 30, 2018
Filed with the SEC on Oct 16, 2018 and accepted by EDGAR at Oct 15, 2018, 20:21 ET.
Management's discussion and analysis
As filed, 17,993 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The purpose of this Management’s Discussion and Analysis ("MD&A") is to provide an understanding of the Company's consolidated financial condition, results of operations and cash and should be read in conjunction with our unaudited condensed financial statements and related notes that appear elsewhere in this Quarterly Report on Form 10-Q for the three and six months ended September 30, 2018, and the Annual Report on Form 10-K filed with the SEC on June 21, 2018. The Company’s actual results could differ materially from those discussed here. Factors that could cause differences include those discussed in the “Risk Factors” section, as well as discussed elsewhere in this report.
Company Background
We are a Maryland corporation formed in April 2005. Our principal place of business is in Maryland, U.S.A. Our operational subsidiaries are in Hong Kong and India.
Our Business
IGC Management’s focus is to develop and commercialize cannabinoid based alternative therapies for indications such as Alzheimer’s disease, Parkinson’s disease, and pain. Our flagship product Hyalolextm, is not a U.S. Food and Drug Administration (“FDA”) approved pharmaceutical product. It is a cannabinoid based alternative oral combination therapy whose active ingredients have been shown to help alleviate symptoms associated with Alzheimer’s disease. The commercialization of Hyalolextm has commenced and we expect revenue in fiscal year 2019, though there can be no assurance as to the amount of such revenue. The Company recently entered the hemp oil / cannabidiol (CBD) infused beverage space and expects to bring a sugar free CBD infused energy drink to market. The Company has filed several patents for its pipeline of products including ones for the treatment of Alzheimer’s, Parkinson’s and Central Nervous System related disorders, pain, eating disorders, seizures in cats and dogs, and an energy drink. In addition, since inception, the Company operates a legacy business that involves trading commodities and heavy equipment rental. Our revenue currently comes from our legacy business.
Business Segments and Revenue Contribution
The Company has two business segments: legacy infrastructure, and medical cannabis based alternative therapies. The legacy business has two drivers: (a) trading of infrastructure commodities like steel, and iron ore, among others, and (b) rental of heavy equipment. The legacy infrastructure business contributed 100% of the revenue in the quarter ended September 30, 2018. In fiscal year ending March 31, 2018, our lead product Hyalolextm was in its research and development phase, and in fiscal year ending March 31, 2019, we began production in anticipation of commercialization.
(In thousands)
| Revenue Segments | Three Months Ended September 30, 2018 |
|---|---|
| Legacy infrastructure | $811 |
| Alternative therapies | - |
| Total IGC | $811 |
Segment 1: Legacy Infrastructure
Since our inception, we have participated in various aspects of the infrastructure industry. During the fiscal year ended March 31, 2018, we streamlined our legacy infrastructure business to infrastructure commodity trading and heavy equipment rental. We trade infrastructure commodities like steel and iron ore, among others, and we rent heavy equipment. Our subsidiary, Techni Bharathi Private Ltd (“TBL”) in India is responsible for heavy equipment rental, and its subsidiary IGC Enterprises Ltd. Operating in Hong Kong is responsible for infrastructure trading. We exited the real estate management business conducted through our Malaysian subsidiary Cabaran Ultima and now we account for it as “Investment Held for Sale” at a fair value of $147,500. We expect to dispose Cabaran Ultima.
Our strategy for the legacy business is to maintain annual revenue of $3 to $5 million and focus on growing margin by reducing the cost of operations and by investments in heavy equipment.
Segment 2: Alternative therapies (Complementary and Alternative Medicine, “CAM”)
We focus on the development and commercialization of cannabinoid-based combination therapies. None of our products or therapies are FDA approved pharmaceuticals. Cannabinoids are chemical compounds that exert a range of effects on the body, including impacting the immune response, gastrointestinal maintenance and motility, muscle functioning, and nervous system response and functioning. Phytocannabinoids are cannabinoids that occur naturally in the cannabis plant. Some of the compounds found in the cannabis plant are (i) the THC (delta-9-tetrahydrocannabinol) or main psychoactive component with many therapeutic uses, and (ii) the non-psychoactive phytocannabinoid, CBD (Cannabidiol), which may be used to provide relief to a variety of symptoms including pain, seizures, and eating disorders.
Our work and strategy are to use cannabinoids synergistically with other active ingredients that in many cases have been established to treat specific conditions. We seek, through the synergies for our combination therapies, to decrease side effects, increase bio-availability, and enhanced efficacy. This strategy in some cases leads to “new and improved” products, and in others it results in totally novel products with surprising results, as in the case of Hyalolextm, our product for Alzheimer’s Disease.
Other complimentary products that we have in the pipeline are IGC-501 for indications of neuropathic pain; Serosapse for indications of Parkinson’s and other Central Nervous System (CNS) disorders; Caesafin for seizures in cats and dogs; and Natrinol for indications of cancer and AIDS induced nausea and vomiting. None of these are FDA approved and they are not considered to be pharmaceutical drugs. They fall in the category of nutraceuticals, supplements or Complimentary Alternative Medicines (CAMS). We are also working on a hemp-oil-CBD-infused energy drink.
Our growth and expansion strategies are to commercialize and license our products in states and countries where we can legally enter the market.
We have filed provisional patents with the United States Patent and Trademark Office (“USPTO”), in the phytocannabinoid-based combination therapy space, for the indications of pain, medical refractory epilepsy, and cachexia, and to protect the intellectual property for our hemp-oil-CBD-infused energy drink. In addition, in May 2017, we acquired an exclusive license to a patent filed by the University of South Florida Research Foundation entitled “Cannabidiol and Synthetic Dronabinol for treatment of Alzheimer’s Disease.” Although, the Company believes the registration of patents is an important part of its business strategy and its success depends in part on such registration, the Company cannot guarantee that such patent filings will result in a successful registration with the USPTO.
The Company has also developed and deployed a QR code-based system that allows patients to access a website with information on our alternative medicine products, specific to a state. As the number of states in which the product is available increases, we expect to expand the backend to a blockchain that allows for inputs directly from growers, processors, and dispensaries. This information will collectively display product identification and product origination by providing the patient with information regarding the origin, chemicals, and processes used to manufacture the product. We expect to expand the QR code-based system in several phases over fiscal 2019.
For more in-depth information regarding our industry, products, services and corporate history, please refer to the Company’s Annual Report on Form 10-K filed with the SEC on June 21, 2018.
Results of Operations
Three Months ended September 30, 2018, Compared to Three Months ended September 30, 2017
Statement of Operations
(in thousands, unaudited)
| Three Months Ended September 30, 2018 | 2017 | Change | Percent Change | |
|---|---|---|---|---|
| Revenue | $811 | $235 | $576 | 245.10% |
| Direct Cost | (793) | (163) | (630) | 386.50% |
| Selling, general and administrative expenses | (873) | (335) | (538) | 160.59% |
| Operating loss | $(855) | $(263) | $(592) | 225.09% |
| Other loss - net | (3) | (41) | 38 | (92.68)% |
| Income before income taxes and minority interest attributable to non-controlling interest | $(858) | $(304) | $(554) | 182.23% |
| Tax expense/(benefit) | - | - | ||
| Loss after income taxes | $(858) | $(304) | $(554) | 182.23% |
Revenue - Total revenue was about $811 thousand and about $235 thousand for the three months ended September 30, 2018, and 2017, respectively. This represents an increase in revenue of about $576 thousand or about 245 %. In the three-month period ended September 30, 2018, our revenue arose from trading commodities and the equipment rental businesses. The increase in total revenue is attributable to an increase in the volume of trading in different types of steel and other infrastructure related material in and outside of India. Our focus in the current year is to increase margins and further de-risk the trading business.
Direct Cost (excluding depreciation) – Direct Cost increased to about $793 thousand for the three months ended September 30, 2018, compared to $163 thousand for the three months ended September 30, 2017. The increase in direct cost is from the increased revenue and associated expenses for the procurement of material. We expect to move the trading business to higher margin commodities, like river sand, and establish larger supplier contracts.
Selling, General and Administrative Expenses - Selling, general and administrative expenses (SG&A) was about $873 thousand for the three months ended September 30, 2018, compared to about $335 thousand for the three months ended September 30, 2017. SG&A consists primarily of depreciation, research and development, employee related expenses, professional fees, other corporate expenses, allocated overhead and provisions, and write-offs relating to doubtful accounts and advances. The SG&A increase of about $538 thousand or about 160 % during the quarter ended September 30, 2018, is primarily related to non-cash expenses recorded for the grant of options or shares to employees, advisors, and contractors.
Net loss – Net loss was about $858 thousand and about $304 thousand for the three-month periods ended September 30, 2018, and 2017, respectively. The $554 thousand increase in loss (182 % increase) is attributable to an increase in SG&A as explained above.
Six Months ended September 30, 2018, Compared to Six Months ended September 30, 2017
Statement of Operations
(in thousands, unaudited)
| Six Months Ended September 30, 2018 | 2017 | Change | Percent Change | |
|---|---|---|---|---|
| Revenue | $2,289 | $289 | $2,000 | 692% |
| Direct Cost | (2,229) | (170) | (2,059) | 1,211% |
| Selling, general and administrative expenses | (1,427) | (721) | (706) | 97% |
| Operating loss | $(1,367) | $(602) | $(765) | 127% |
| Other loss – net | (4) | (77) | 73 | (94)% |
| Income before income taxes and minority interest attributable to non-controlling interest | $(1,371) | $(679) | $(692) | 101% |
| Tax expense/(benefit) | ||||
| Loss after income taxes | $(1,371) | $(679) | $(692) | 101% |
Revenue - Total revenue was about $2.29 million for the six months ended September 30, 2018, compared to about $289 thousand for the six months ended September 30, 2017. This represents an increase of $2 million or 692 %. In the six-month period ended September 30, 2018, our revenue arose from trading commodities and the equipment rental businesses. In the previous year we reorganized our structure to move the trading business out of our previously acquired subsidiary to an in-house lower-overhead model. The increase in total revenue is a reflection of that transition and is attributable to an increase in the volume of trading commodities in and outside of India. Our focus in the current year is to increase margins and further de-risk the trading business. We expect to achieve this through long term contracts that were previously not possible due to our limited financial resources.
Direct Cost (excluding depreciation) – The direct cost for the six months ended September 30, 2018, was about $2.22 million, compared to about $170 thousand for the six months ended September 30, 2017. The increase in the direct cost stems from an increase in the volume of business, as reflected in the increase in revenue, and is related to the steel trading and rental business.
Selling, General and Administrative - Selling, general and administrative expenses (SG&A) was approximately $1.42 million for the six months ended September 30, 2018, compared to $721 thousand for the six months ended September 30, 2017. SG&A consists primarily of depreciation, research and development, employee related expenses, professional fees, other corporate expenses, allocated overhead and provisions, and write-offs relating to doubtful accounts and advances. The SG&A increase of $707 thousand or 97.91 % during the six months ended September 30, 2018, is primarily from the allocation of non-cash expenses related to the grant of stock awards in fiscal year ended March 31, 2018.
Net loss – Net loss was approximately $1.37 million and approximately $679 thousand for the six-month periods ended September 30, 2018 and 2017, respectively.
Liquidity and Capital Resources
This liquidity and capital resources discussion compares the unaudited consolidated company financials for the six-month periods ended September 30, 2018, and 2017.
(in thousands, unaudited)
| Six Months Ended September 30, 2018 | 2017 | Change | Percent Change | |
|---|---|---|---|---|
| Cash, cash equivalents and marketable securities | $6,408 | $597 | $5,811 | 973% |
| Cash in foreign subsidiaries | 52 | 409 | (357) | (87%) |
| Property, plant and equipment, net | 5,675 | 953 | 4,722 | 495% |
| Working capital | 5,237 | 804 | 4,433 | 551% |
| Cash used in operating activities | (851) | (627) | (224) | 35% |
| Cash used in investing activities | (16) | (148) | 132 | (89%) |
| Cash provided by financing activities | $5,683 | 844 | $4,839 | 573% |
At the end of September 30, 2018, the Company had about $6.41 million in cash and cash equivalents. In the quarter ended September 30, 2018, the non-GAAP total cash burn after adjusting for non-cash items that include ESOPs and other payments made with common stock, is about $506 thousand. The cash burn is primarily associated with public company expenses, increased product R&D, production, and getting Hyalolextm ready for market, among others.
The Company believes that it has adequate financial resources to meets its short-term goals including marketing Hyalolex, developing and marketing a drink formulation, marketing several other complimentary medications, initiating filings with the FDA and conducting small clinical trials, amongst others.
During the six months ended September 30, 2018, cash used in operating activities of about $851 thousand was a result of $1.37 million of net loss, non- cash adjustments to net income of $446 thousand and a decrease in the net change in operating assets and liabilities of $74 thousand.
Cash provided by financing activities of $5.68 million during the six months ended September 30, 2018, consisted primarily of funds raised by the sale of equity shares through the Company’s ATM programs.
Off-Balance Sheet Arrangements
On September 22, 2018, and October 1, 2018, the Company entered into two At-the-Market Offering Agreements with The Benchmark Company, LLC (“Benchmark”) and ViewTrade Securities, Inc. (“ViewTrade” and together with Benchmark, the “Managers”) pursuant to which the Managers acted as the Company’s sales agents with respect to the issuance and sale of up to an aggregate of $30,000,000 of the Company’s shares of common stock, par value $0.0001 per share (the “Shares”), from time to time in an at-the-market public offering (the “Offering”).
Sales of the Shares through the Managers were made directly on the NYSE American, on any other existing trading market for our common stock or to or through a market maker. The Managers did not sell the Shares in privately negotiated transactions. The Company paid its Managers a commission equal to 5.0% of the gross proceeds from the sale of the Shares pursuant to the Sales Agreement. The Shares were sold and issued pursuant the Company’s shelf registration statements on Form S-3 (File No. 333-201822), which became effective on April 8, 2015, and (File No. 333-224082), which was declared effective by the Securities and Exchange Commission on May 11, 2018 (the “Registration Statement”), and a related prospectus supplement.
Critical Accounting Policies
While all accounting policies impact the financial statements, certain policies may be viewed as critical. Critical accounting policies are those that are both most important to the portrayal of financial condition and results of operations and that require management’s most subjective or complex judgments and estimates. Our management believes the policies that fall within this category are the policies on revenue recognition, goodwill, inventories, accounts receivable, impairment of long-lived assets and investments, stock-based compensation, and cybersecurity.
Please see our disclosures on Notes 2 - Summary of Significant Accounting Policies to the Notes to the Unaudited Consolidated Financial Statements in this report and to the Notes to the Audited Consolidated Financial Statements in Part II of our Annual Report on Form 10-K, filed with the SEC on June 21, 2018, as well as Item 7. Management’s Discussion and Analysis of Financial Conditions and Results of Operations on the same annual report, for a discussion of all our critical and significant accounting policies.
Market risk
As filed, 159 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Pursuant to Item 305(e) of Regulation S-K, the Company is not required to provide the information required by this Item as it is a “smaller reporting company.”
Controls and procedures
As filed, 2,086 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
As of the end of the period covered by this report, management conducted an evaluation, under the supervision and with the participation of its Chief Executive Officer (CEO), its principal financial officer (PFO) and its principal accounting officer (PAO), of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rules 13a-15 and 15d-15 of the Securities Exchange Act of 1934. In designing and evaluating the disclosure controls and procedures, our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that our management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.
Based upon that evaluation, our CEO, PFO and PAO concluded that our disclosure controls and procedures were designed a reasonable assurance level and were effective to reasonably ensure that information we are required to disclosed in reports under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms, and that such information is accumulated and communicated to the Company’s management, including its principal executive officer, principal financial officer and principal accounting officer, as appropriate, to allow timely decisions regarding required disclosures.
Changes in Internal Control over Financial Reporting
There were no changes in our internal controls over financial reporting during our fiscal quarter ended September 30, 2018, which were identified in conjunction with Management’s evaluation required by paragraph (d) of Rule 13a-15 and 15d-15 under the Exchange Act that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.
Risk factors
As filed, 6,827 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The risk factors below update and complement the risk factors previously disclosed in the Company’s annual report on Form 10-K for the fiscal year ended March 31, 2018.
The non-passage of the 2018 Farm bill can be detrimental to our stock price.
The Agricultural Act of 2014, which became law on February 7, 2014, is also known as the Farm Bill. Section 7606 of this federal statute, titled “Legitimacy of Industrial Hemp Research,” gave authorization to state departments of agriculture and institutions of higher learning, in states that have legalized hemp cultivation, to grow the crop for research and pilot programs. Since the implementation of the Farm Bill, more than 30 states have passed laws regarding industrial hemp.
The 2018 Farm Bill, if passed, includes the Hemp Farming Act of 2018, which will remove hemp as a designated as controlled substance, legalizing the crop under federal law, which will allow CBD derived from hemp to be legally sold in all 50 states. The Bill, which has the support of Senate Majority Leader Mitch McConnell, is awaiting congressional approval, which would replace the 2017 Farm Bill, which expired on September 30th.
The CBD infused energy drink, as well as Hyalolex and some of our other products, may be redesigned to use hemp-based extracts rendering them federally legal in all 50 states. This opens up the market well beyond the medical cannabis market. However, non-passage of the bill will impact our ability to sell products in all 50 states and could be detrimental to the price of our stock.
Cannabis remains illegal under U.S federal law, and therefore, strict enforcement of federal laws regarding medical-use cannabis would likely result in slower growth of our business plans, and/or delisting from the NYSE American.
In the U.S., cannabis is a Schedule I controlled substance under the Controlled Substances Act (CSA). Even in those jurisdictions in which the manufacture and use of medical cannabis has been legalized at the state level, the possession, use and cultivation of cannabis remain violations of federal law that are punishable by imprisonment and substantial fines. Moreover, individuals and entities may violate federal law if they intentionally aid and abet another in violating these federal controlled substance laws or conspire with another to violate them.
The U.S. Supreme Court has ruled in United States v. Oakland Cannabis Buyers' Coop. and Gonzales v. Raich that it is the federal government that has the right to regulate and criminalize cannabis, even for medical purposes. If the federal government were to strictly enforce federal law regarding cannabis, we may not be able to license our product in the U.S. for sale to medical cannabis patients, or we may be subject to federal prosecution. While, these could lead to delisting from the NYSE American, it would not stop us from sales in other parts of the world including Canada and Germany, among others.
Although, the Company does not directly sell cannabis our formulations when licensed to U.S. processors could be construed as aiding and abetting the licensee or others to violate federal controlled substance laws or to conspire with them to violate the laws. While, there are companies listed on the NYSE that service the medical cannabis industry, it is unclear if the NYSE American will apply their findings uniformly. Revenue from licensing medical cannabis formulations directly to entities in the U.S., could lead to a delisting from the NYSE American. However, it would not stop the Company from sales in other parts of the world where medical cannabis is legal. A delisting from the NYSE American would require the Company to list on the OTC exchange in the U.S., which may adversely affect the price of our common stock.
In January 2018, the U.S. Department of Justice (DOJ) rescinded certain memoranda, including the so-called “Cole Memo” issued on August 29, 2013 under the Obama Administration, which had characterized enforcement of federal cannabis prohibitions under the CSA to prosecute those complying with state regulatory systems allowing the use, manufacture and distribution of medical cannabis as an inefficient use of federal investigative and prosecutorial resources when state regulatory and enforcement efforts are effective with respect to enumerated federal enforcement priorities under the CSA. The impact of the DOJ's recent rescission of the Cole Memo and related memoranda is unclear but may result in the DOJ increasing its enforcement actions against the regulated cannabis industry generally, including processors, growers and dispensaries. This essentially would mean that our market in the U.S. would evaporate, greatly diminishing the scope of our business plan, in the short term, as the U.S. represents 90% of the current cannabis market. However, long term, the trend of the U.S. dominating the cannabis market is changing as other countries introduce medical cannabis legislation.
Congress previously enacted an omnibus spending bill that includes a provision prohibiting the DOJ (which includes the DEA) from using funds appropriated by that bill to prevent states from implementing their medical-use cannabis laws. This provision, however, expires on September 30, 2018, and must be renewed by Congress.
Additionally, financial transactions involving proceeds generated by cannabis-related conduct can form the basis for prosecution under the federal money laundering statutes, unlicensed money transmitter statutes and the Bank Secrecy Act. Prior to the DOJ's rescission of the “Cole Memo,” supplemental guidance from the DOJ issued under the Obama Administration directed federal prosecutors to consider the federal enforcement priorities enumerated in the “Cole Memo” when determining whether to charge institutions or individuals with any of the financial crimes described above based upon cannabis-related activity. It is unclear what impact the recent rescission of the “Cole Memo” will have, but federal prosecutors may increase enforcement activities against institutions or individuals that are conducting financial transactions related to cannabis activities.
Federal prosecutors have significant discretion and no assurance can be given that the federal prosecutor in each judicial district where we license our product will not choose to strictly enforce the federal laws governing cannabis production or distribution. Any change in the federal government's enforcement posture with respect to state-licensed cultivation of medical-use cannabis, including the enforcement postures of individual federal prosecutors in judicial districts where we license products, would eliminate or slow down our ability to execute our business plan, which would adversely affect the trading price of our securities.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2018-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2018-07-01 to 2018-09-30 | $811.0k | us-gaap:Revenues |
| Revenue | 6 months2018-04-01 to 2018-09-30 | $2.3m | us-gaap:Revenues |
| Cost of revenue | 3 months2018-07-01 to 2018-09-30 | $793.0k | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2018-04-01 to 2018-09-30 | $2.2m | us-gaap:CostOfRevenue |
| Research and development | 3 months2018-07-01 to 2018-09-30 | $237.0k | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2018-07-01 to 2018-09-30 | $873.0k | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2018-04-01 to 2018-09-30 | $1.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2018-07-01 to 2018-09-30 | −$855.0k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2018-04-01 to 2018-09-30 | −$1.4m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2018-07-01 to 2018-09-30 | −$858.0k | us-gaap:NetIncomeLoss |
| Net income | 6 months2018-04-01 to 2018-09-30 | −$1.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2018-07-01 to 2018-09-30 | −$0.03 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months2018-04-01 to 2018-09-30 | −$0.04 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months2018-04-01 to 2018-09-30 | −$851.0k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2018-04-01 to 2018-09-30 | $3.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2018-09-30 | $6.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2018-09-30 | $7.7m | us-gaap:AssetsCurrent |
| Total assets | At period end2018-09-30 | $16.6m | us-gaap:Assets |
| Current liabilities | At period end2018-09-30 | $2.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2018-09-30 | $2.7m | us-gaap:Liabilities |
| Shareholders' equity | At period end2018-09-30 | $13.8m | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2018-10-09 | 36,347,769 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001185185-18-001848. Last ingested by Listed: Nov 6, 2026, 16:27 ET. Listed shows no prices and gives no investment advice.